Fig. 3

Anticancer activity of HDACs/mTOR inhibitor 1 in vitro. A Schematic review of screening of latent compounds for combination in an anti-pancreatic cancer library of 1453 compounds in PATU 8988-T. B Cell viability of PATU 8988-T treated with compounds (2 μmol/L) combined with pyrotinib (2 μmol/L) for 72 h. The ranking of the relative anticancer activity is shown by the heatmap; each block represents 1 compound. C Single agent anticancer activity (y-axis), combination agent anticancer activity (x-axis) and fold change of x and y (z-axis) were depicted in a 3D coordinate in C and red dots showing compounds content with screening threshold: single agent anticancer activity < 0.5, combination anticancer activity > 0.7 and fold change > 2. D Numbers of compounds content with thresholds listed in venn diagram. E CFPAC-1 and AsPC-1 as well as PATU 8988-T treated with 38 selected compounds (1 μmol/L) and pyrotinib (1 μmol/L) for 72 h and cell viabilities were calculated. F Chemical structure of HDACs/mTOR inhibitor 1. G 4 cell liens were treated with HDACs/mTOR inhibitor 1 (0.5 μmol/L), pyrotinib (1 μmol/L) or combination regiments. Data are represented as mean ± SEM. Statistical significance was assessed using a Student t test. *P < 0.05, **P < 0.01, ***P < 0.001. ns not significant